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Abstract: The aim of study to empirically evaluate the health care 
professional attitude towards the pharmaceutical products in context to 
the Pakistan pharmaceutical market current situation, that why are 
national companies’ brands more consider than multinationals, based on 
primary data collected through self-administered questionnaire by field 
visits to 250 health care professional. Results of explanatory sequential 
method indicates that product efficacy is the primary factor to 
considered, followed by sales representative, promotional material and 
price factor including; some influence of new launches, packaging and 
availability of the products are reported. However the bio equivalence 
report and patient demands are rarely considered by HCP. 
Key Words: Generic brands, Research brands, Promotional mix, Health care 
professionals. 
Introduction 
Pharmaceutical industry is among the most scientific industries of the world. It is 
estimated by the intercontinental marketing services prognoses (2016) that the 
pharmaceutical market around the globe in terms of revenues is approximately 1.2 
trillion US dollars. In which the majority of revenues about 50% are generated by 
western markets. However, it is forecasted by IMS (2016) future growth trends of 
pharmaceutical industry favor the Asia Pacific market. According to IMS health (2013) 
this economic shift of growth from western markets to Asian markets is indeed, due to 
the shift of global spending on pharmaceutical products from branded to generic based 
brands (copy product). It is expected that generic products shares will achieve 63% of 
the market share by the end 2017, which was 58% in the year 2012. Further this growth 
trend of generic brands is bigger than research brands, which seems uniform regardless 
of the markets either pharmerging or merged markets (developing or developed 
markets).  
According to business monitoring international (2015) Pakistan pharmaceutical 
industry is the part of pharmerging markets. Its market size is approximately 2.3 billion 
US dollars. This is expanding with 12% cumulative annual growth rate (CAGR). 
According to research and markets (2016) national companies in Pakistan holding 60% 
of the market shares, the rest of 40% are with multinational companies, which was 
40:60 in late 90‟s. National companies businesses primarily depends on generic 
products (copy product), while multinational mainly depends on their research products 
(branded). Hence Pakistan pharmaceutical market current situation makes the problem 
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under investigation, that why are national pharmaceutical companies brands more 
consider than multinationals in case of Pakistan‟s pharmaceutical? 
Pharmaceutical companies in Pakistan promote their products to the health care 
professional (HCP) through direct and indirect marketing activities. The HCP get 
informed and influenced from the pharmaceutical companies in different manners to 
prescribe any product. Thereby; this study mainly documents the HCP perspective in 
context to marketing activities of pharmaceuticals, that how HCP consider the 
pharmaceutical marketing practices, while prescribing any product (Generic/Branded) 
to treat their patients.  
Literature Review 
Worldwide literature on pharmaceutical industry marketing is widely available, 
however, in Pakistan prospects are that research work can be further expanded 
regarding pharmaceutical marketing practices. Below are some relevant published 
papers on pharmaceutical marketing practices As Tajdar et al (2015) HCP prescribing 
behavior can be influenced by many factors e.g. Medical representative, product price 
and efficacy of the drug including companies‟ indirect marketing activities. They have 
investigated that the product price, medical representative and country of origin of the 
product significantly impact on the HCP prescribing behavior. It has seen in study of 
Ahmed et al (2014) promotional material also can influence over the prescribing 
behavior of HCP. They have also highlighted the importance of other factors that HCP 
generally consider like patient demands, new launches and sales representative of the 
pharmaceutical companies. According to Shamim et al (2014) new drug launches and 
the promotional materials, which are being used by pharmaceutical companies, have 
differentiating impact over the HCP. Jamshed et al (2011) stresses on HCP to prefer 
generic brands for patient‟s affordability, he further suggested HCP should consider 
equally important bio equivalence or clinical reports, before to prescribing any generic 
product (copy product) directly into patients. Below (Appendix C) comprehend a 
summarized form of relevant literature specifically highlighting methodology, variables 
and key findings of the studies. 
 
Literature Gaps 
The above mentioned and (Appendix C) published studies have their own attributes 
and contribution towards the development of literature for pharmaceutical marketing 
practices. However there is need to fill the gaps of some studies and their effects on 
HCP prescribing behavior. For example, the term promotional material is being used 
by authors for pharmaceutical promotional materials as a broad term. There is need to 
define the term promotional material that; what actually it consist or what sort of 
material comes under this definition? It is important to know that what factors actually 
stimulates the HCP to consider any product, in context to the 4 P‟s of marketing mix. 
More importantly, from the literature it has been observed that the studies have 
identified many variables and has established their influencing role over HCP 
prescribing/considering behavior. For example; product price, country of origin of the 
product, sales representative, new launches and bio equivalence or clinical reports 
including patient demands. However, it is important to give an ordinal sequence to all 
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those identified variables, to know the preferences of HCP among these identified 
variables that how HCP will rate these variables on ordinal scale on the basis of their 
importance, while prescribing/considering any product (generic/branded) to treat 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pre Conceptual Framework  
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Figure 2  Post Conceptual Framework 
From the literature review, it has been revealed that there are many factors that can 
possibly stimulate health care professional to prescribe a product. However, for better 
understanding and confirmation of these variables, few interviews were conducted with 
pharmaceutical industry experts. Some variables are identified after conducting 
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professional to prescribe a product. On the basis of literature review and interviews 
with industry experts, the conceptual frame work has been classified as pre-conceptual 
framework (figure 1) and post-conceptual frame work (figure 2). Pre-conceptual frame 
work primarily depends on the factors that were identified during a literature review. 
While the post-conceptual frame work consists of the literature review as well as 
interviewed-identified variables. After a thorough review of literature and interviews, 
these identified variables were reclassified (see appendix A) on the basis of their nature 
and scope of marketing in the context of 4 - Ps of the marketing mix. This classification 
has helped to draft questionnaire theme based on six variables. The variables are sales 
representative, price factor, promotional material, new launch, bioequivalence and 
patient demands; that possibly can stimulate HCP to prescribe a product. 
Besides through interviews the term „promotional material‟ is  explained in detail 
which means that there are 35 types (see appendix B) of different goods and services, 
which pharmaceutical companies are using named as promotional material/mix 
Hypotheses 
According to Ahmed et al. (2012), the importance of generic products cannot be denied 
due to the affordability of generic products as compared to multinational brands. 
Therefore, generic products should be more preferred than multinational brands. 
However, the bioequivalence report of the generic brands is equally important and 
should be considered by the HCP in same manners like affordability is considered for 
generic brands. It has also endorsed by the Ahmed and Saeed (2014) that the qualities 
of national companies‟ products have been remarkably improved. National companies‟ 
products are providing clinical results to the HCP for their patients. However, the 
clinical trials are essential for generic products before using generic brands directly into 
patients.  This direct use of generic products cannot be allowed only on the basis of 
pharmaceutical equivalence (physical resemblances). This study has selected the 
bioequivalence or clinical reports (interchangeably use words) variable to test the 
practices of HCP and pharmaceutical companies about bioequivalence or clinical 
reports. To know how well HCP are aware and consider these important reports during 
practice below hypothesis is being set to establish the fact about bioequivalence reports 
and, its ordinal number among other identified variables. 
H1: Generic brands are prescribing because of bio equivalence (BE) 
Moreover, in views of different authors like Lanjouw (2005) and Ahmed et al. (2012), 
the role of new launches either in the form of new packaging or new molecular formula 
has got importance to influence the HCP prescribing behavior. According to Shafiq et 
al. (2011), new product launch “marketing campaigns messages” are being exaggerated 
by the pharmaceutical marketers to influence the HCP. In views of Baig (2016), to 
exaggerate the brand campaign messages, they draft it in an emotional context by using 
the words like “halal” and  “free from alcohol” targeting spiritual beliefs and values to 
influence the HCP prescribing behaviors towards the new product launch. This is also 
endorsed by the Chandra sekaran (2013). However, there is need to identify the amount 
of influence of the new product launch on HCP prescribing behavior. Therefore; the 
following hypothesis has been designed to find the ordinal number and the impact of 
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new product launch either in the form of new packing or a new molecular formula on 
the prescription behavior of HCP; 
H2: Generic brands are prescribing because of new launches (NL) 
According to Narendran and Narendranathan (2013), pharmaceutical companies‟ 
promotional material significantly influences the HCP prescribing behavior. In views 
of Tahir et al. (2013), HCP generally takes different kinds of gifts from pharmaceutical 
companies including expensive goods like perfumes and wrist watches. HCP also 
demands different types of goods and services which could be anything either of ethical 
or unethical nature. According to Siddiqi et al. (2011), “HCP prescription is 
significantly influenced by the scientific tools than all other things”, which is contrary 
to what Ahmed et al. (2011), maintains. According to Kremer et al. (2008) “direct to 
HCP promotional material has very high elasticity than direct to price elasticity in 
studies where the price has been taken as an independent variable”.  Thus, to 
investigate the relationship between HCPs prescribing behavior and the promotional 
materials used by the pharmaceutical companies, the following hypothesis is being set 
to establish the ordinal number of promotional material among the other identified 
variables. 
H3: Generic brands are prescribing because of promotional mix (PM)  
Ahmed and Sattar (2014) have found that “medical representative plays an important 
role while developing a relationship with HCP on behalf of pharmaceutical company”. 
Similarly, Fugh and Ahari (2007) has provided the evidence that how pharmaceutical 
representatives scripted and trained to make a relationship with customers in order to 
influence them for prescription. This is also explained by Tajdar et al. (2015) that “a 
medical representative‟s has a very influencing role over HCP prescribing behavior. 
According to Shetty & Gujarathi (2013), the employee personal branding has got very 
much importance while branding the organization or organizational brands to the 
market. In this ongoing trial, the below hypothesis is being set in order to know the 
sequential order of „medical representative‟ as an influencing factor among all other 
selected factors?    
H4: Generic brands are prescribing because of sales representative rapport SR)  
According to Najmi et al. (1998), most of the time HCP feels neither under-pressure 
nor monitored by the country health system, that whether HCP prescribe the product in 
an appropriate way or not, to treat the patients. Even lack of demand and knowledge is 
observed in patients to ask about medicines from HCP. This shows that the sole 
decision maker is HCP to prescribe any product. While contrary to the findings of 
Nejmi et al., Ahmed et al. (2012) stated that the importance of „patient demand‟ for 
particular products usually is well entertained by the HCP. Therefore, to hypothetically 
test the situation and establish the ordinal sequence following hypothesis has been set, 
H5: Generic brands are prescribing because of patient demands (PD) 
Furthermore, „affordability‟ is the key factor while treating patients with medicines. 
According to Chintagunta and Desiraju (2005), pricing has a strategic importance all 
over the world. This is aligned with research results of Tajdar et al. (2015) which has 
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demonstrated high importance of the role of price on HCP prescribing behavior. It is 
also mentioned by Ahmed et al. (2012) and Jamshed et al. (2011). In views of Vogler 
(2012), medicines prices are kept low for generic products to increase the accessibility 
and affordability for those patients who pay out of their pockets. However, in the 
reimbursement cases, theprice is notmandatory concern for stakeholders.  Kremer et al. 
(2008) maintains that price does impact on HCP prescribing behaviors as an 
independent variable. In this investigation, the below hypothesis has been set to testify 
and know the ordinal number of price factors on the sequential ladder that can possibly 
influence or not the HCP prescribing behavior.  
H6: Generic brands are prescribing because of price factor (RS) 
Methodology 
This research is based on mixed method of research adopted from Creswell (2014) 
explanatory sequential design. The primary data was collected from HCP by dividing 
them into two broad categories; practicing physicians and practicing surgeons from the 
3 teaching hospital of Peshawar (lady reading hospital, Khyber Teaching Hospital and 
Hayatabad Medical Complex) each category has 20 units on an average and 5 
consultants in each unit along with 10 residence medical officers as well 8 house 
officers. 50% of sample size of the total population (Approx 220 respondents) was 
conveniently selected, besides 30 top class general practitioners (GPs) who had 
participated as freelancers. Data was collected through self-administered questionnaire 
composed of 19 closed ended questions and one open ended question, questionnaire 
theme was based on post conceptual frame work. Initially through literature review one 
preliminary questionnaire was developed which later restructured according to the local 
practices and industry experts opinions. The reliability of the questionnaire was equal 
to “Cronbach Alpha 0.71”.  For the analysis of data multiple regressions were applied 
through SPSS. In second phase, for qualitative analysis the follow up explanation 
model was conducted. In which randomly visited to 20 physician, 20 surgeons and 10 
general practitioners to validate the quantitative interpretations in view of market 
practices. 
Results 
Table 1 Regression Model Summary 
Model R R Square Adjusted Std. Error of the Estimate 
1 0. 647
a
 0.418 0.404 0.56642 
a:  (Constant) Predictor: PM, SR, RS, NL, BE, PD. 
Result of R-square suggests that approx. 42% (0.418) of the variation is explained by 
the independent variables in the dependent variable, representing the amount of change 
occurring in HCP prescription behavior due to the predictors / marketing activities of 
pharmaceutical companies (Table 1). 
The ANOVA test values (Table 2) are indicating that the overall model is statistically 
significant (0.000). 
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Table 2 ANOVA 
Model 
Sum of 
Squares Df 
Mean 
Square F P-value. 
1 
Regression 56.062 6 9.344 29.12 0.000
a
 
Residual 77.963 243 0.321 
  Total 134.025 249       
 
Table 3 Coefficient 
Model 
Un  Std 
Std  
Coefficients 
T P-value. B 
Std. 
Error Beta 
(Constant) 0.946 0.273 
 
3.469 0.001 
Promotional  
Mix (PM) 0.242 0.067 0.208 3.61 0 
Sales  Rep (SR) 0.354 0.055 0.386 6.454 0 
Product Price 
(RS)  0.171 0.075 0.144 2.265 0.024 
New launch 
(NL) 0.098 0.049 0.104 2.011 0.045 
Patient  Demand 
(PD) -0.047 0.046 -0.05 -1.014 0.312 
Bio Equivalence 
(BE) -0.035 0.04 -0.043 -0.869 0.386 
b: (Dependent variable): HPB. 
Findings of the coefficient results (table 3) indicated that the HCP prescribing behavior 
has a direct dependence on investigated variables which are sales representative (SR), 
promotional mix (PM) and price factor (RS) including new launches (NL) of the 
products (significant at 5% confidence interval). However, bioequivalence (BE) and 
patient demands (PD) are immaterial to health care professionals and has no 
dependence (insignificant at 5% confidence interval). The significant along with 
insignificant results have been re-confirmed in qualitative analysis, that were follow-up 
visits to HCP, in which it has been revealed through open-ended questions that in 
practice, health care professionals do not ask from pharmaceutical companies to 
provide bioequivalence or clinical reports. The HCP emphasize on pharmaceutical 
equivalence or empirical results of the generic products instead of bioequivalence or 
clinical reports. HCP also mentioned that they do not entertain patient demands for 
particular product. Because HCP generally follow the prescribing protocols approved 
by the food and drug administration (FDA) or health regularity entities. Moreover, the 
availability of the product in nearby pharmacy or institution has somewhat influence 
over the prescription of HCP. 
  
184 |  Vol. II, Issue II (ISSN No. 2414-2336) 
 
Discussion  
Previous studies show that the prescribing behavior of HCP depends on many factors. 
Pharmaceutical companies are using different tools to influence the prescribing 
behavior of health care professionals in order to increase their business shares. The aim 
of the research study was to understand that why national companies are more 
prescribing than multinational companie incase of Pakistan pharmaceutical industry. 
For this research purpose, 250 participants‟ responses were analyzed on the basis of 
identified variables and set hypothesis. The overall result of the study was significant 
and aligned with previous literature diagnosis in regards to the marketing practices of 
pharmaceutical companies. Further, it has been inferred  why national companies are 
more growing than multinationals on the basis of results that give an ordinal sequence 
which is product efficacy on priority followed by a sales representative, promotional 
mix and price factor including new launches in terms of new packaging or 
advancement in formula and availability of the products. 
On the basis of ordinal sequence, we can say that quality of national companies‟ 
products has been improved to compete with multinational products. Therefore, HCP 
are prescribing national companies' brands more as stated by Ahmed & Sattar (2014). 
National companies‟ sales representatives are more successful in building a good 
rapport with customers. They are more frequent to provide and remind the right 
information about their products as compared to a multinational sales representative. 
Theresearch study results are contrary to Siddiqi et al. (2011) who mentioned that 
scientific tools are more influencing than other promotional tools. Although scientific 
tools come under the umbrella of promotional tools because any type of investment on 
HCP with objectives to yield prescription comes under the marketing expenditure for 
companies. National companies are spending more on the promotional mix (tools) to 
support sales representatives to aggressively promote their brands in the market. While 
on other hand, multinational companies having limited promotional tools list pre-
approved from international federation of pharmaceutical manufacturer association 
(IFPMA) and the central office of the company. Beside this, the national companies‟ 
products are more economical than multinational brands. This is another reason for 
getting more prescriptions from national brands than multinationals. Another very 
important aspect for the organization prosperity is organic growth that is also favoring 
the national companies. Because national companies new launching are at a higher side 
with advancement in drug molecule, manufacturing technique and product packagings 
for patient‟s compliance. These are the factor that goes into national companies favor. 
Therefore, their market expansion rate is higher than multinationals. The two factors go 
probably into multinational favor which is bioequivalence and patient demands, 
unfortunately, are immaterial for HCP in Pakistan pharmaceutical market.  
According to Tajdar (2015) who has proven that the price and medical reps having 
significant influence over HCP prescribing behavior. The research  study results are in 
line with additional explanation that is the degree of significance of these variables on 
HCP prescribing behavior in terms of the ordinal sequence. Moreover, Ahmed et al. 
(2014) also found that medical reps and promotional tools have significant influence on 
HCP prescribing behavior. In this regard, this study has provided a detailed list of 
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promotional tools that pharmaceutical companies are using in Pakistan market 
(Appendix B). Apart from this, Jamshed et al. (2011) have stated that the price and 
medical reps play an important role in influencing the HCP prescribing behavior. This 
research results show alignment with above findings with further explanation of HCP 
preferences. It has also been proved that patient demand and bioequivalence has a very 
limited role in influencing the HCP prescribing behavior as described by Ahmed et al. 
(2012). 
Conclusion 
The results of this study witnessed that in Pakistan pharmaceutical market, national 
companies products are more considered than multinationals by the HCP. On the basis 
of results it can be inferred that help to give an ordinal sequence to all those factors 
which have been tested. According to the ordinal sequence, at 1
st
, there is the product 
efficacy to cure the disease or disease symptoms, followed by the sales representative 
role on 2
nd
 and at 3
rd
the promotional mix are highly influencing factors for the health 
care professionals. Besides these, the product price is at 4
th
 and new launches are at 5
th
 
either in the form of new packing or new molecules, including product availability 
(nearby institution/formulary) at 6
th
 have low influencing effects on HCP prescribing 
behavior.   
Contribution of the Study 
The study will have a practical impact based on conclusion presented, which could help 
to give an ordinal sequence (see conclusion for ordinal sequence) to all those 
pharmaceutical marketing factors, which can possibly influence the HCP. This ordinal 
sequence will help to understand HCP preferences in terms of ordinal number, when 
HCP prescribe product (generic/branded) to treat patients.  
Policy Recommendations 
Pharmaceutical multinationals in Pakistan can resume their contribution shares by 
adapting the national companies marketing approach. In which national companies are 
more HCP centric than patients. While multinational companies are more patients 
centric than HCP. Earlier this study has proved that patient demands are rarely consider 
by HCP. The sole authority to prescribe a product is with HCP. Hence shifting the 
centre of activities can help to resume the market shares. In case of constraints to 
adapting national companies approach, as contingencies; multinational should 
outsource (give marketing rights) their products to the national companies can help to 
achieve the productivity of business operations in Pakistan market. 
Limitation of the Study 
There are some factors which are beyond the scope of the study. For example, 
Pakistan‟s political, economic and law order situations. These factors can impact the 
businesses in either way as barrier or driver. Besides companies standard operating 
procedure (SOP) can also affect the decision-making process of business operations in 
Pakistan. 
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Appendix: A 
Stimulation factors from marketing prospects: 
4 - P’s Attributes Categories 
Product 
1. Product Efficacy 
1. Bio Equivalence (BE)   
2. Product Quality 
3. Product Safety 
4. Product dosage 
5. Comparative trials 
6. New Molecule 
2 New Launches (NL)  7. New Packing 
8. Availability 
Price 9. Affordability 3. Product Price (RS) 
Promotion 
10. Type of material  
4. Promotional Material 
(PM) 
11. Type of campaign 
12. Company image 
13. Sales representative 
5. Sale Representative (SR) 
14.    Senior influence 
Place 
15. Patient Need 
6. Patient Demand (PD) 16. Patient Disease 
17. Patient obligation 
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Appendix B 
Promotional materials named as promotional mix 
Source: Literature review and industry expert interviews 
Appendix: C 
Summary of Previous Studies 
R
es
ea
rc
h
 
Methodology Variable Findings 
T
a
jd
a
r 
et
 a
l,
 (
2
0
1
5
) Self-administered 
questionnaire, 
Samples Size 100 
from local Peshawar 
hospitals. Technique 
- Chi Square, 
frequency tables. 
Country of origin 
(COO), Price, and 
medical 
representative. 
Prescription of physician can 
influence by many factors, 
including price, medical rep, 
and country of origin along 
with companies senior 
management. 
Promotional Mix (Tools)  
1. Drug samples. 
2. Product brochures. 
3. Medical books. 
4. Clinical reports. 
5. Brand presentations. 
6. CME: Local / Int. 
7. Foreign trips. 
8. Events, celebrations. 
9. Events are sponsored. 
10. Medical journals. 
11. Special events 
12. Family events. 
13. New Year calendars. 
14. Diagnostic equipments. 
15. Magazines Add. 
16. Instruments. 
17. Round table discussions. 
18. Product pens. 
19. Paper pads / Slips. 
20. Table organizers. 
21. Office equipments. 
22. Personalized gifts. 
23. Stationary. 
24. Free drug camps. 
25. Free diagnostics camps. 
26. Food, refreshments. 
27. Free hotelling / Picnics. 
28. Cash donations. 
29. Office renovation / Decoration. 
30. Ward renovation / Decoration 
31. Free registration for events. 
32. Trade schemes / Bonuses. 
33. Printings. 
34. Speaker presentation. 
35. Personnel relationship 
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A
h
m
ed
 e
t 
a
l,
 (
2
0
1
4
) 1. Self-administered 
questionnaires, 
Samples size 100, all 
were doctors. 
Technique - Multiple 
Regressions. 
Physician 
Prescribing 
Behaviors-  
Product samples, 
Literatures, Gifts / 
Give-away & CME 
(continue medical 
education) Round 
table discussion. 
The researcher concluded that 
all the promotional material 
can influence the prescribing 
behavior of physicians.  
Medical rep’s knowledge and 
personal relationship. 
S
h
a
m
im
 e
t 
a
l,
 (
2
0
1
4
) Primary data via 
questionnaire 
(Likert Scale: 1 to 5) 
Samples size 263, 
Technique – 
Regression and   
Factor analysis 
Physician 
Prescribing 
Behaviors. 
New drug 
Brand 
prescriptions 
ponsorship 
Promotional Tools 
Drug samples 
Result suggested that new 
drug, promotional tools and 
drug samples significantly 
affect the prescribing behavior 
of physicians.  
A
h
m
ed
 &
 S
a
tt
a
r,
 (
2
0
1
4
) Secondary data on 
current 
pharmaceutical 
marketing Mix 
(Tools) using by 
companies in 
Pakistan to promote 
their Products. 
Strategies & 
approaches. 
1. Product Chain  
2. Prescription 
Chain 
3. Products Types 
4. Types of mix 
(Tools): 
Samples/Literature
s 
Gifts/Giveaways 
Symposium/CME 
(continue medical 
education 
E-Marketing/table 
discussion 
Personal Relations 
The quality of medicines and 
effectiveness of marketing 
teams has remarkably 
improved to compete the 
multinationals. Direct to 
consumer marketing is yet to 
gain ground in Pakistan. 
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A
h
m
ed
 &
 S
a
ee
d
, 
(2
0
1
4
) 
Primary data via 
questionnaire, 
Samples size 300 
from Karachi. 
Technique  -  
Multiple Regression 
Unethical practices 
in pharmaceutical 
industry. 
Pharmaceutical 
companies 
Doctors 
Hopitals 
Pharmacies 
Govt. Officials 
Patients 
Pharmaceutical companies 
and doctors both are 
responsible for unethical 
practices. However the levels 
of unethical practices are 
higher at rural area than the 
urban area of Karachi. 
N
a
re
n
d
ra
n
 &
 N
a
re
n
d
ra
n
a
th
a
n
, 
(2
0
1
3
) 
Primary data via  
questionnaire 
Sample size 50 
Doctors & 53 sales 
persons.  Technique -  
Regression analysis, 
graphical 
presentation 
Physician 
Prescription 
Behavior: 
36 different 
independent 
variables in context 
to: 
Direct Marketing 
Personal Selling 
Advertisement 
Public Relationship 
Sales Promotions 
Pharmaceutical marketing 
significantly  
nfluencing the physician 
prescription behaviors. 
K
h
a
n
  
et
 a
l,
 (
2
0
1
3
) 
Primary data via. 
Self-administered 
questionnaire, samples 
size 400. 
Technique -  Regression 
Analysis 
Emergence of 
unethical practices 
and influencing 
factors like 
Doctors, 
Companies, sales 
promotion officer 
and Patients 
35% doctors believe that 
doctors are responsible for the 
emergence of unethical 
practices while 46% replied 
that pharmaceutical 
companies are responsible. 
A
k
h
ta
r 
et
 a
l,
 (
2
0
1
3
) Primary data via 
questionnaire. 
Sample size 20 GP 
200 patients.  
Technique - 
Spearman, non-
parametric. 
Generic 
prescription, price 
and drug 
prescribing 
protocol. 
Result suggested that 0% 
generic prescription and no 
single prescription was 
prescribed in accordance with 
national drug prescribing 
policy or FDA – WHO 
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A
h
m
ed
 e
t 
a
l,
 (
2
0
1
2
) 
Primary data via 
questionnaire. 
Samples size 250 
doctors from Karachi 
area GP & 
Physicians.  
Technique-Chi-
Square, Mega state 
software. 
Physician 
prescription 
behavior: 
Patient demand, 
where does a 
patient get 
information, 
Condition where 
the Physician 
prefers to prescribe 
generic drug, 
pharmaceutical 
companies 
influence, 
Unbiased drug 
data. 
General practitioner & 
Physician prescribe generic 
drugs mainly because of drug 
representative regular visits & 
cheaper drugs. 
J
a
m
sh
ed
 e
t 
a
l,
 (
2
0
1
1
) 
Primary data semi 
structured long 
interviews. Sample 
size 11 dispensing 
doctors 9 males& 
3female.  Technique  
-   descriptive 
analysis. 
Level of knowledge 
about generic, 
attitude towards 
generic, perception 
about generic and 
marketing 
practices of 
companies for 
generics. 
The generic should be more 
prefer. However bio 
equivalence testing and 
rigorous guideline are 
required before prescribing 
generic. 
Z
a
m
a
n
, 
(2
0
1
1
) Secondary data from 
IMS and PEC. 
Technique  -   
descriptive analysis. 
Current 
pharmaceutical 
marketing 
strategies and 
future 
pharmaceutical 
marketing 
strategies. 
Right marketing strategy can 
bring results for companies, 
Like: Digital marketing, 
internet and multi channels. 
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S
id
d
iq
i 
e
t 
a
l,
 (
2
0
1
1
) 
Cross sectional 
survey. Sample size 
200 doctors and 200 
medical 
representatives. 
Primary data via 
questionnaire 
adapted from Girish 
et al Technique  -   
Regression analysis. 
Physician 
Prescription 
Behavior:Influenci
ng factors on 
physician 
prescribing 
behavior. 
Physician prescription more 
influenced by scientific tools 
than any other promotional 
tools. Medical representative 
had similar perception. 
A
h
m
ed
 e
t 
a
l,
 (
2
0
1
1
) 
Sample size 400 
doctors and 100 
pharmaceutical 
companies. Primary 
data via self-
administered 
questionnaire. 
Technique -   Graphs, 
Frequency tables. 
Physician 
perception about 
marketing tactics 
using by 
pharmaceutical 
companies in 
ethical contexts. 
58% of doctors believe that 
pharmaceutical marketing 
practices are unethical. 
H
a
k
o
n
se
n
, 
(2
0
1
1
) 
Sample size 83 
Pakistani with an 
average age of 58 
years. 
Branded 
medicines, 
Substitute 
medicines with 
different names 
and the satisfaction 
of patients. 
Substitute or generic 
medicines may have negative 
effects on Pakistani 
immigrants in Oslo. 
M
a
so
o
d
 e
t 
a
l,
 (
2
0
0
9
) 
Secondary data,to 
provide a detailed 
basis to understand 
pharmaceuticals 
marketing practices. 
Types of tools 
using by 
pharmaceutical 
companies and 
their abuse used. 
All the codes of conduct, self-
regulations and laws 
developed to control 
pharmaceutical promotion 
and marketing seem 
ineffective. 
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L
a
n
jo
u
w
, 
(2
0
0
5
) 
The descriptive and 
explanatory research, 
Secondary data, 
Sample size 22 
countries by dividing 
on the basis of 
income classes. 
Technique (s) -   
Regression analysis. 
Patents, Price 
Control, 
New Drug, Market 
entry and affects 
the patient access 
to the medicines 
Patents and price can affect 
the patient access to new 
molecules in poor countries; 
however, in high income 
earning countries does not 
matter. 
 
